Assertio Holdings (ASRT): Growth-Adjusted Market Cap to Net Income
Supply chain optimization for neurological products has ensured high margins for Assertio Holdings, Inc. (ASRT), which is available for analysis on GURU.Markets via the P/E to growth rate trend. The value of 0.00 represents the current reading of this metric. This was made possible through billing digitalization and production outsourcing, as well as the stabilization of sales under Heather Mason's leadership following the asset restructuring.
Analytical breakdowns for Assertio Holdings, Inc. (ASRT)
- price and consensus price forecast:
- stock exchange capitalization data:
- company book value details:
- debt obligations and liquidity statistics:
Aggregate Debt to Capital Assertio Holdings, Inc.|ASRT - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient assertiotx.com|ASRT - Company Debts|Debts to Book Value Assertio Therapeutics|ASRT - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Assertio|Intermediate Coverage Ratio assertiotx.com
- earnings and multiples data:
ASRT - Company Net Income|Expected Net Profit Assertio Holdings, Inc.|ASRT - Price to Earnings Ratio|Future Price to Earnings assertiotx.com|ASRT - PEG Multiple|Enterprise Value to Operating Income Before Depreciation Assertio Therapeutics|ASRT - Operating profit EBITDA|Net earnings per share for the last four quarters Assertio|ASRT - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months assertiotx.com|ASRT - Earnings growth in current year|Net earnings per one share growth forecast for next year Assertio Holdings, Inc.
Fundamental company analysis:ASRT - Assertio Holdings
Assertio Holdings, Inc. (ASRT) is reducing its reliance on individual patents and stabilizing profit inflows through the diversification of its neurological drug portfolio. The current PEG ratio correlates the P/E market valuation with these growth rates to determine the fairness of the capitalization. A value below one signals that the asset is undervalued relative to its expansion. This chart reveals gaps between operational success and the share price. Investors utilize this filter to identify undervalued "moonshots."
Who Assertio Holdings, Inc. competes with
Growth-Adjusted Market Cap to Net Income Biogen Inc|Price/Earnings to Growth Ratio Neurocrine Biosciences Inc NBIX|Growth-Adjusted Market Cap to Net Income Regencell Corp (RGC)|Axsome Therapeutics - PEG Multiple|Price to Earnings Adjusted for Growth Rate acadia-pharm.com|Xenon (XENE) - Price/Earnings to Growth Ratio|Viking Therapeutics Inc - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple SUPN|CPRX (Catalyst Corp) - Company Value to Earnings Growth Ratio|PEG Multiple DNLI|Growth-Adjusted Market Cap to Net Income harmonybiosciences.com|Price/Earnings to Growth Ratio Biohaven BHVN|Amylyx Pharmaceuticals Inc (AMLX) - Price to Earnings Adjusted for Growth Rate|TRVI: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio PRAX (Praxis Corp)|AVXL: PEG Multiple|ceribell.com - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Prothena Corporation plc|Price to Earnings Adjusted for Growth Rate Alector Therapeutics ALEC|Price/Earnings to Growth Ratio Annexon Inc. (ANNX)|Price/Earnings to Growth Ratio OMER (omeros.com)|PEG Multiple NGNE (Neurogene Inc.)|ACIU: Growth-Adjusted P/E Ratio|Voyager Therapeutics, Inc. - PEG Multiple|Growth-Adjusted Market Cap to Net Income Neumora NMRA|Scilex Holding Co. (SCLX) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio TVGN|ACOG (Alpha Cognition Inc) - PEG Multiple|CGTX - Price to Net Income Growth Ratio|Price/Earnings to Growth Ratio Inhibikase Therapeutics, Inc. (IKT)|Growth-Adjusted Market Cap to Net Income Cassava Sciences Inc|Coya Therapeutics - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio VTGN|Ovid Rx - PEG Multiple|Growth-Adjusted Market Cap to Net Income acumenpharm.com ABOS|CervoMed (CRVO) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio ATHE|CLNN (Clene Inc) - PEG Multiple|Price/Earnings to Growth Multiple PepGen Corp (PEPG)|Price/Earnings to Growth Multiple JUNS (Jupiter Neurosciences Inc)|Growth-Adjusted Market Cap to Net Income relmada.com|PEG Multiple ANVS (Annovis Bio)|PEG Multiple Grace Therapeutics Inc GRCE|AIFF - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Klotho Neurosciences Inc KLTO|neurosense-tx.com (NRSN) - Price/Earnings to Growth Ratio|revivapharma.com - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple MTVA|NRXS (NeurAxis Inc.) - Company Value to Earnings Growth Ratio|Price/Earnings to Growth Ratio Helius Medical (HSDT)|passagebio.com - Growth-Adjusted P/E Ratio|PEG Multiple NEUP (Neuphoria Therapeutics)|minervaneurosciences.com (NERV) - Price to Earnings Adjusted for Growth Rate|ATHA: Price/Earnings to Growth Multiple|ADXN - PEG Multiple|alzamend.com (ALZN) - Price/Earnings to Growth Ratio|Cyclerion Therapeutics, Inc. - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Protagenic Therapeutics Inc.|Price to Earnings Adjusted for Growth Rate Pasithea KTTA|PEG Multiple CRGT|PEG Multiple Avenue Therapeutics Inc. (ATXI)|Price/Earnings to Growth Ratio Brainstorm Cell Therapeutics, Inc. BCLI|Growth-Adjusted Market Cap to Net Income Cara Therapeutics Inc (CARA)|CHRO - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Eliem Therapeutics ELYM|ITCI: PEG Multiple|Price to Earnings Adjusted for Growth Rate Longboard Pharmaceuticals Inc (LBPH)|Price/Earnings to Growth Ratio Marinus|NKGN: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple NRBO (NeuroBo Pharmaceuticals)|Company Value to Earnings Growth Ratio SAGE|PEG Multiple SNPX (Synaptogenix)|Growth-Adjusted Market Cap to Net Income Trevena Inc. (TRVN)|VIGL - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Anew Medical Inc.|CERE (Cerevel Therapeutics) - Price/Earnings to Growth Multiple
